Neuronetics Inc   (STIM)
Other Ticker:  
Price: $3.2900 $0.01 0.305%
Day's High: $3.34 Week Perf: 6.13 %
Day's Low: $ 3.09 30 Day Perf: -4.64 %
Volume (M): 97 52 Wk High: $ 5.81
Volume (M$): $ 318 52 Wk Avg: $2.29
Open: $3.30 52 Wk Low: $1.03

 Market Capitalization (Millions $) 95
 Shares Outstanding (Millions) 29
 Employees -
 Revenues (TTM) (Millions $) 68
 Net Income (TTM) (Millions $) -33
 Cash Flow (TTM) (Millions $) -38
 Capital Exp. (TTM) (Millions $) 2

Neuronetics Inc
Neuronetics Inc is a medical technology company that focuses on developing and commercializing non-invasive brain stimulation therapies for patients with psychiatric and neurological disorders. The company's flagship product is NeuroStar Advanced Therapy, which utilizes transcranial magnetic stimulation (TMS) to target specific areas of the brain involved in mood regulation.

NeuroStar Advanced Therapy is FDA-approved for the treatment of major depressive disorder (MDD) and is backed by clinical studies demonstrating its effectiveness. The procedure involves the use of a non-invasive device that delivers magnetic pulses to the brain, stimulating the nerve cells involved in mood regulation.

Neuronetics Inc is committed to providing alternative treatment options for patients who have not responded well to traditional therapies, such as medication or talk therapy. They aim to improve patients' quality of life by reducing symptoms of depression and other psychiatric disorders.

The company is based in Malvern, Pennsylvania, and collaborates with healthcare professionals, researchers, and patients to advance the understanding and adoption of TMS therapy. Neuronetics Inc is dedicated to ongoing research and development to expand the applications of TMS technology and improve patient outcomes in the field of mental health.

   Company Address: 3222 Phoenixville Pike Malvern 19355 PA
   Company Phone Number: 640-4202   Stock Exchange / Ticker: NASDAQ STIM
   STIM is expected to report next financial results on March 06, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Product Service News

Neuronetics Unveils Future-Ready TrakStar Patient Data Management System, Boosting Workflow Efficiencies for NeuroStar TMS Providers

Published Mon, Feb 12 2024 1:32 PM UTC

Neuronetics, a leading medical technology company, has recently introduced the latest iteration of its TrakStar Patient Data Management System. This innovative system is poised to revolutionize the workflow efficiencies for NeuroStar Transcranial Magnetic Stimulation (TMS) providers, ensuring improved patient care and outcomes. By interpreting the articles Neuronetics Launch...

Product Service News

Augmenting Neurological Therapy: Lucet Health Eases Access to NeuroStar TMS Treatment for Depression

Published Tue, Feb 6 2024 1:28 PM UTC

The landscape of mental health treatment is changing at an unprecedented pace, and at the heart of this transformation is a big change from Lucet Health, which is set to massively improve accessibility to Transcranial Magnetic Stimulation (TMS), a pioneering neurological therapy. Lucet Health, a prominent health insurance company, has updated its policy and changed its crite...

Management Announcement

Revolutionizing Depression Treatment: NeuroStar TMS Grabs Expanded Approval, Redefining Hope in Japan }, finish_reaso

Published Mon, Dec 4 2023 1:56 PM UTC

Technological Advances Streamline and Enhance MDD Treatment: NeuroStar TMS Receives Expanded Regulatory Approval in Japan
In recent news, Neuronetics Inc. has experienced a staggering 42.96% increase in shares following the expanded regulatory approval of their groundbreaking invention, the NeuroStar TMS system, in Japan. This milestone represents a significant step forw...

Neuronetics Inc

STIM Achieves Solid Growth in Financial Performance for the Period Ending September 30, 20232.

/>Neuronetics Inc., a medical technology company specializing in neurohealth disorders, recently released its financial results for the third quarter ending September 30, 2023. The report highlights several key facts, including the company's revenue growth, shortfall per share, and notable increases in inventories and accounts receivable. This article aims to provide an overview and analysis of Neuronetics Inc.'s financial performance, offering insights into its recent achievements and potential challenges.
Revenue Growth:
Neuronetics Inc. witnessed a significant increase in revenue during the third quarter of 2023 compared to the same period in the previous year. The company recorded a 7.674% growth, reaching $17.76 million, surpassing the Medical Equipment & Supplies industry's average increase of 4.03%. Additionally, there was a sequential growth of 5.902% from the preceding quarter's revenue of $16.77 million. These figures indicate a strong market presence and robust demand for Neuronetics' products.


Neuronetics Grants Inducement Awards to New Employees, Demonstrating Commitment to Neurohealth Innovation

Published Mon, Nov 6 2023 9:30 PM UTC

In a recent press release, Neuronetics, Inc., a leading medical technology company specializing in improving the quality of life for patients with neurohealth disorders, announced the granting of inducement awards to four new non-executive employees. These awards, in the form of Restricted Stock Units (RSUs), represent a total of 18,000 shares of the company's common st...


Neuronetics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com